N-乙基-N,N',N'-三甲基乙烷-1,2-二胺 | 106-64-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-乙基-N,N',N'-三甲基乙烷-1,2-二胺
• 中文别名: 2-(N-乙基甲基氨基)乙基二甲胺
• 英文名称: N-ethyl-N,N',N'-trimethylethylenediamine
• 英文别名: N-ethyl-N,N',N'-trimethyethyldiamine；2-(N-Ethylmethylamino)ethyldimethylamine；N'-ethyl-N,N,N'-trimethylethane-1,2-diamine
• CAS: 106-64-9
• 化学式: C₇H₁₈N₂
• 分子量: 130.233
• InChiKey: ZOBHKNDSXINZGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2921290000

反应信息

• 作为反应物：
  描述：

  六氟磷酸钾 、 [RuCl2(benzene)]2 、 N-乙基-N,N',N'-三甲基乙烷-1,2-二胺 以 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Organometallic ionic liquids from half-sandwich Ru(II) complexes with various chelating ligands

  摘要：

  Salts comprising of cationic half-sandwich Ru(II) complexes with various chelating ligands and the bis (trifluoromethanesulfonyl) amide anion (Tf2N-) were prepared. These salts can be represented as [(arene) RuCl(L-L)][Tf2N] (arene = C6Me5Bu, C6Me6, p-cymene, C6H6; L-L = 2-Py-CH2NHCMe2Et, 2-Py-CH= NC6H13, H13C6NHCH2CH2NHC6H13, Me2NCH2CH2SC4H9, Me2CN=CHCH=NCMe2). Two of the eight salts are liquids at room temperature (similar to 20 degrees C), while the other salts are solids with melting points of 60-130 degrees C. Upon cooling from the melt, most salts exhibited glass transitions between -30 degrees C and -5 degrees C. The salts were found to catalyze the oxidation of cyclohexanol although decomposition occurred during the reaction. Crystal structures of related salts were also determined. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2015.09.009
• 作为产物：
  描述：

  N-乙基乙二胺 、 聚合甲醛 在 甲酸 作用下， 以 水 为溶剂， 以54%的产率得到N-乙基-N,N',N'-三甲基乙烷-1,2-二胺
  参考文献：
  名称：

  二胺的烷基取代对含有 N-烷基乙二胺、乙酰丙酮酸盐和硝酸盐配体的镍 (II) 混合配体配合物的配位几何学和配体场强的影响

  摘要：

  已经研究了镍 (II) 混合配体配合物的结构和光谱特性，[Ni(Me 4 en)(acac)(NO 3 )] (1), [Ni(EtMe3en)(acac)(NO 3 )] ( 2), [Ni(asym-Et 2 Me 2 en)(acac)(NO 3 )] (3), [Ni(Et3Meen)(acac)(N03)] (4), 和 [Ni(Et 4 en) (acac)(NO 3 )] (5) (Me 4 en = N,N,N',N'-四甲基乙二胺，EtMe 3 en = N-乙基-N,N',N'-三甲基-乙二胺，不对称Et 2 Me 2 en = N,N-二乙基-N',N'-二甲基乙二胺，Et 3 Meen = N,N,N'-三乙基-N'-甲基-乙二胺，Et 4 en = N,N,N' ,N'-四乙基乙二胺，acac = 乙酰丙酮化物）。已经确定了配合物 2 和 3 的晶体结构。这些配合物具有

  DOI：

  10.1246/bcsj.82.230

文献信息

• [EN] 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK<br/>[FR] AMIDES HÉTÉROCYCLIQUES À 5 CHAÎNONS ET BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019014308A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE CYCLOSPORINE ET LEURS UTILISATIONS
  申请人：S&T GLOBAL INC

  公开号：WO2017200984A1

  公开（公告）日：2017-11-23

  A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

  公开了化合物的公式（I）：（I）或其药学上可接受的盐，其中符号如规范中定义。还描述了包含相同化合物的药物组合物，以及使用该药物组合物治疗或预防病毒感染、炎症、干眼症、中枢神经障碍、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺部和肝脏疾病、肾脏疾病和脱发的方法。
• BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION COMPRISING LIPID PARTICLE, AND KIT
  申请人：KABUSHIKI KAISHA TOSHIBA

  公开号：US20200270217A1

  公开（公告）日：2020-08-27

  The present embodiment provides a compound represented by the formula (1): Q-CHR 2 (1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

  本实施例提供了一种由以下公式表示的化合物： Q-CHR2（1） （其中Q是含有两个或更多三级氮但不含氧的含氮脂肪族基团，R是含有可生物降解基团的脂肪族基团）。通过将该化合物与其他脂质结合，如能够减少聚集的脂质，可以形成脂质颗粒。此外，该化合物可用于制备药物组合物，以将活化剂输送到细胞内。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。